Cash Cash Equivalents - Gensight Biologics SA (PAR:SIGHT) - Alpha Spread

Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.38 EUR -3.8%
Market Cap: 39.3m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Gensight Biologics SA
Cash & Cash Equivalents Peer Comparison

Comparables:
VLA
NANO
IPH
GNFT
ALERS

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Cash & Cash Equivalents
€2.1m
CAGR 3-Years
-62%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash & Cash Equivalents
€131.4m
CAGR 3-Years
-26%
CAGR 5-Years
24%
CAGR 10-Years
15%
Nanobiotix SA
PAR:NANO
Cash & Cash Equivalents
€75.3m
CAGR 3-Years
-14%
CAGR 5-Years
16%
CAGR 10-Years
31%
Innate Pharma SA
PAR:IPH
Cash & Cash Equivalents
€70m
CAGR 3-Years
-12%
CAGR 5-Years
-14%
CAGR 10-Years
-1%
Genfit SA
NASDAQ:GNFT
Cash & Cash Equivalents
€77.8m
CAGR 3-Years
-23%
CAGR 5-Years
-18%
CAGR 10-Years
14%
Eurobio Scientific SA
PAR:ALERS
Cash & Cash Equivalents
€89m
CAGR 3-Years
11%
CAGR 5-Years
52%
CAGR 10-Years
32%

See Also

What is Gensight Biologics SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.1m EUR

Based on the financial report for Dec 31, 2023, Gensight Biologics SA's Cash & Cash Equivalents amounts to 2.1m EUR.

What is Gensight Biologics SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-39%

Over the last year, the Cash & Cash Equivalents growth was -80%. The average annual Cash & Cash Equivalents growth rates for Gensight Biologics SA have been -62% over the past three years , -39% over the past five years .

Back to Top